ClinicaliQ Trial Snapshot
- A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) — Active Not Recruiting • Phase II • NCT06924970.
- Trial testing tebapivat against placebo in sickle cell disease patients to find the best dose for improving hemoglobin levels.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD. Conditions: Sickle Cell Disease Interventions: Tebapivat, Tebapivat Matched Placebo Lead Sponsor: Agios Pharmaceuticals, Inc. Planned Enrollment: 59 participants